SDC1 and Miyoshi myopathy: In a proof of concept phase 1/2 trial, a single therapeutic dose of the murine anti-CD138 IgG1 mAb B-B4 coupled to iodine-131 was administrated as monotherapy to three relapsed/refractory MM patients who received at least three prior lines of treatment (189).